Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared on X:
“In Annals of Oncology, results from a new phase 3 trial (HELEN Trio011) showing improved pCR with PD1-blockade added to carbo/taxotere for TNBC. Together with NeoPACT, these results offer an alternative, anthracycline-sparing neoadjuvant regimen for TNBC.”
To which Aya Mohamed, Breast CA Specialist and Researcher, added:
“Encouraging results for anthracycline-free chemoimmunotherapy in TNBC.
The key question:
Whether the pCR benefit translates into durable EFS/OS gains and how this approach compares with KEYNOTE-522.
Long-term data will be critical.”
Title: Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial
Authors: D. Jiao, X. Sun, J. Qiao, H. Jia, X. Liu, H. Dai, C. Zhang Y. Wei, B. Chen, Y. Sun, J. Yu, L. Zou, L. Li, Y. Feng, M. Yan, L. Liu, X. Wang, Y. Zhou, P. Lu, W. Wang, F. Ji, L. Jia, B. Zhao, X. Guo, Y. Sun, T. Huang, J. Wu, M. Lü, J. Zhu, J. Zhang, J. Wang, H. Yang, P. Wang, L. Niu, Z. Pang, Y. Xiang, Z. Lu, X. Chen, C. Wang, Z. Liu.
Read the full article.
This also can be interesting:
